Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 , a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
TP-03 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
TomaGold Announces Closing of First Tranche of Private Placement Featuring Strategic Investment from SIDEX and NQIM
